Nivolumab is a fully human IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor. By modulating immune checkpoints, nivolumab enhances the body’s antitumor immune response and has transformed the…
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) used in the treatment of several advanced and metastatic cancers. It inhibits multiple pathways involved in tumor growth, angiogenesis, and metastasis, making…
What is Ipilimumab? Ipilimumab is a humanized monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a key immune checkpoint receptor that downregulates immune activation. By blocking CTLA-4, ipilimumab enhances…